{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:42:59Z","timestamp":1793209379158,"version":"4.5.0"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cancer drug development is a complex and costly process. Selinexor is a drug that received accelerated approval as a new treatment for relapsed or refractory diffuse-large B-cell lymphoma and multiple myeloma. Despite initially showing promise in treating these conditions, it has shown high-grade toxicity in clinical trials. Hence, an analysis is needed to assess the clinical trial portfolio of selinexor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This investigation aims to evaluate published clinical trials of selinexor to assess its risk\/benefit in terms of response and survival outcomes as well as its toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Cross-sectional.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a cross-sectional investigation by searching databases for published clinical trials that used a response criteria pertaining to selinexor administration in adults. In a masked, duplicate manner, we extracted trial characteristics, median progression-free survival (PFS), overall survival (OS), objective response rates (ORR), and Grade 3\u20135 adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 753 articles identified, 40 were included in our final sample. The trials reporting PFS data using control arms showed a median difference in PFS by 4.4 months, favoring the selinexor treatment arm. However, trials that reported OS data with control arms indicated that selinexor showed a worse median difference in OS (\u22122.4 months) than the control arms. Among the 53 measurements reporting ORR, the weighted median ORR was 36.4%, and the median difference ORR (4.8%) favored selinexor. Additionally, 4153 cumulative Grade 3\u20135 AEs were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In comparison to a control arm, selinexor increases PFS and induces response, suggesting drug activity. However, acceptable Grade 3\u20135 AEs or improvement of OS was not seen across a single indication, suggesting a poor pretest probability. Our risk\/benefit analysis of selinexor provides valuable insight into the unfavorable outcomes of the drug and increased high-grade AEs. Hence, further testing of selinexor should be carefully scrutinized and contextualized with the portfolio of data we present.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207251329174","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T08:03:31Z","timestamp":1748678611000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["An evaluation of selinexor\u2019s clinical trial portfolio: a cross-sectional study"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4764-4503","authenticated-orcid":false,"given":"Annes","family":"Elfar","sequence":"first","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, 1111 West 17th Street, Tulsa, OK 74107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew V.","family":"Tran","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Case","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole","family":"Wayant","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griffin K.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"McIntire","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Gardner","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chase","family":"Ladd","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriana M.","family":"Pe\u00f1a","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Tuia","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Vassar","sequence":"additional","affiliation":[{"name":"Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA"},{"name":"Department of Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60329-9"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.11813"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2786"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2016.01.012"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.293"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.3601"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30744-2"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.4845"},{"key":"e_1_3_4_10_2","article-title":"Benefit, risk, and outcomes in drug development: a systematic review of Sunitinib","volume":"108","author":"Carlisle B","unstructured":"Carlisle B, Demko N, Freeman G, et al. Benefit, risk, and outcomes in drug development: a systematic review of Sunitinib. J Natl Cancer Inst; 108: djv292.","journal-title":"J Natl Cancer Inst"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0287-0"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.115"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12430"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000866"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S267404"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008735"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30020179"},{"key":"e_1_3_4_19_2","unstructured":"Hughes G McIntire R Hightower B et al. OSF https:\/\/osf.io\/vdr68\/ (2023 accessed 2 August 2023)."},{"key":"e_1_3_4_20_2","unstructured":"Protocol development https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm (2018 accessed 13 December 2022)."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_3_4_23_2","unstructured":"SR-accelerator https:\/\/sr-accelerator.com\/#\/polyglot (2020 accessed 21 July 2023)."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3600"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007959"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3046"},{"key":"e_1_3_4_27_2","unstructured":"Chapter 4: Searching for and selecting studies https:\/\/training.cochrane.org\/handbook\/current\/chapter-04 (2022 accessed 13 July 2023)."},{"key":"e_1_3_4_28_2","unstructured":"Chapter 5: Collecting data https:\/\/training.cochrane.org\/handbook\/current\/chapter-05 (2022 accessed 20 July 2023)."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-psych-010418-102803"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251329174","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207251329174","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251329174","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:17:43Z","timestamp":1777591063000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207251329174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":28,"alternative-id":["10.1177\/20406207251329174"],"URL":"https:\/\/doi.org\/10.1177\/20406207251329174","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"article-number":"20406207251329174"}}